In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works

Trimmomatic: a flexible trimmer for Illumina sequence data

Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · see citing works

The Sequence Alignment/Map format and SAMtools

Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · see citing works

Fast gapped-read alignment with Bowtie 2

Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · see citing works

STAR: ultrafast universal RNA-seq aligner

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · see citing works

BEDTools: a flexible suite of utilities for comparing genomic features

Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437 · see citing works

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · see citing works

FLASH: fast length adjustment of short reads to improve genome assemblies

Magoč, T., & Salzberg, S. L. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr507 · Cited by 15,366 · see citing works

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017

Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32203-7 · Cited by 8,600 · see citing works

From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline

Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687 · see citing works

Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437 · see citing works

Search-and-replace genome editing without double-strand breaks or donor DNA

Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767 · see citing works

Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System

Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., John van der, O. O. S. T., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,750 · see citing works

Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage

Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · see citing works

Sequence Variations in <i>PCSK9,</i> Low LDL, and Protection against Coronary Heart Disease

Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · see citing works

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985 · see citing works

CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens

Concordet, J., & Haeussler, M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky354 · Cited by 2,354 · see citing works

Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases

Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339 · see citing works

CRISPResso2 provides accurate and rapid genome editing sequence analysis

Clement, K., Rees, H. A., Canver, M. C., Gehrke, J. M., Farouni, R., Hsu, J. Y., Cole, M. A., Liu, D. R., Joung, J. K., Bauer, D. E., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0032-3 · Cited by 1,632 · see citing works

The promise and challenge of therapeutic genome editing

Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126 · see citing works

Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells

Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090 · see citing works

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992 · see citing works

Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype

Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951 · see citing works

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.014 · Cited by 878 · see citing works

Full Coverage for Preventive Medications after Myocardial Infarction

Choudhry, N. K., Avorn, J., Glynn, R. J., Antman, E. M., Schneeweiß, S., Toscano, M., Reisman, L., Fernandes, J. F., Spettell, C. M., Lee, J. L.-Y., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1107913 · Cited by 736 · see citing works

Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors

Grünewald, J., Zhou, R., Garcia, S. P., Iyer, S., Lareau, C. A., Aryee, M. J., & Joung, J. K. (2019) · Nature · doi:10.1038/s41586-019-1161-z · Cited by 663 · see citing works

Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote

Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 628 · see citing works

Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing

Ding, Q., Strong, A., Patel, K. M., Ng, S.-L., Gosis, B. S., Regan, S. N., Cowan, C. A., Rader, D. J., & Musunuru, K. (2014) · Circulation Research · doi:10.1161/circresaha.115.304351 · Cited by 522 · see citing works

Directed evolution of adenine base editors with increased activity and therapeutic application

Gaudelli, N. M., Lam, D. K., Rees, H. A., Solá-Esteves, N. M., Barrera, L. A., Born, D. A., Edwards, A., Gehrke, J. M., Lee, S., Liquori, A., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0491-6 · Cited by 518 · see citing works

Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing

Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499 · see citing works

Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis

Zhou, C., Sun, Y., Yan, R., Liu, Y., Zuo, E., Gu, C., Han, L., Wei, Y., Hu, X., Zeng, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1314-0 · Cited by 482 · see citing works

In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice

Koblan, L. W., Erdos, M. R., Wilson, C., Cabral, W. A., Levy, J. M., Xiong, Z., Tavarez, U. L., Davison, L. M., Gete, Y. G., Mao, X., et al. (2021) · Nature · doi:10.1038/s41586-020-03086-7 · Cited by 479 · see citing works

Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy

Ryu, S.-M., Koo, T., Kim, K., Lim, K., Baek, G., Kim, S., Kim, H. S., Kim, D.-E., Lee, H., Chung, E., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4148 · Cited by 442 · see citing works

Treatment of a metabolic liver disease by in vivo genome base editing in adult mice

Villiger, L., Grisch‐Chan, H. M., Lindsay, H. A., Ringnalda, F. C. A. S., Pogliano, C. B., Allegri, G., Fingerhut, R., Häberle, J., Matos, J., Robinson, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0209-1 · Cited by 426 · see citing works

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M., & Burnett, J. R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.039 · Cited by 363 · see citing works

Engineering of CRISPR-Cas12b for human genome editing

Strecker, J. G., Jones, S., Koopal, B., Schmid-Burgk, J. L., Zetsche, B., Gao, L. A., Makarova, K. S., Koonin, E. V., & Zhang, F. (2019) · Nature Communications · doi:10.1038/s41467-018-08224-4 · Cited by 362 · see citing works

Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease

Rodríguez, F., Maron, D. J., Knowles, J. W., Virani, S. S., Lin, S., & Heidenreich, P. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4936 · Cited by 339 · see citing works

Sensitive high-performance liquid chromatographic determination of ionic drugs in biological fluids with short-wavelength ultraviolet detection using column switching combined with ion-pair chromatography: application to basic compounds

Yamashita, K., Motohashi, M., & Yashiki, T. (1989) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)83043-1 · Cited by 285 · see citing works

"Dark" Purkinje cells of the cerebellar cortex.

Leranth, C., & Hámori, J. (1970) · PubMed · Cited by 264 · see citing works

Ligand binding and protein dynamics: a fluorescence depolarization study of aspartate transcarbamylase from Escherichia coli

Royer, C. A., Tauc, P., Hervé, G., & Brochon, J. (1987) · Biochemistry · doi:10.1021/bi00394a027 · Cited by 238 · see citing works

In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing

Chadwick, A. C., Wang, X., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309881 · Cited by 218 · see citing works

In utero CRISPR-mediated therapeutic editing of metabolic genes

Rossidis, A. C., Stratigis, J. D., Chadwick, A. C., Hartman, H. A., Ahn, N. J., Li, H., Singh, K., Coons, B. E., Li, L., Lv, W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0184-6 · Cited by 216 · see citing works

Adenine base editing in an adult mouse model of tyrosinaemia

Song, C.-Q., Jiang, T., Richter, M., Rhym, L. H., Koblan, L. W., Zafra, M. P., Schatoff, E. M., Doman, J. L., Cao, Y., Dow, L. E., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0357-8 · Cited by 200 · see citing works

Genome-wide target specificity of CRISPR RNA-guided adenine base editors

Kim, D., Kim, D.-E., Lee, G., Cho, S.-I., & Kim, J. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0050-1 · Cited by 192 · see citing works

The promise and challenge of therapeutic genome editing

Doudna, & Já (2020) · 四川生理科学杂志 · Cited by 153 · see citing works

Genome-wide profiling of adenine base editor specificity by EndoV-seq

Liang, P., Xie, X., Zhi, S., Sun, H., Zhang, X., Chen, Y., Chen, Y., Xiong, Y., Ma, W., Liu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07988-z · Cited by 148 · see citing works

In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA

Villiger, L., Rothgangl, T., Witzigmann, D., Oka, R., Lin, P. J. C., Qi, W., Janjuha, S., Berk, C., Ringnalda, F., Beattie, M. B., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00671-z · Cited by 105 · see citing works

Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets

Conway, A., Mendel, M., Kim, K., McGovern, K., Boyko, A., Zhang, L., Miller, J. C., DeKelver, R. C., Paschon, D. E., Mui, B. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.003 · Cited by 95 · see citing works

Large-Scale Phenome-Wide Association Study of <i>PCSK9</i> Variants Demonstrates Protection Against Ischemic Stroke

Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., & Ingelsson, E. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002162 · Cited by 60 · see citing works

Low Density Lipoprotein Cholesterol–Lowering Strategies and Population Health

Brandts, J., & Ray, K. K. (2020) · Circulation · doi:10.1161/circulationaha.119.043406 · Cited by 59 · see citing works

Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9

Wang, L., Breton, C. A., Warzecha, C. C., Bell, P. L., Yan, H., He, Z., White, J., Zhu, Y., Li, M., Buza, E. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.020 · Cited by 59 · see citing works

Directed Evolution of Adenine Base Editors with Increased Activity and Therapeutic ApplicationPreprint

Gaudelli, N. M., Lam, D. K., Rees, H. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.13.990630 · Cited by 50 · see citing works

Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors

Hines, D. M., Rane, P., Patel, J. G., Harrison, D. J., & Wade, R. L. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s180496 · Cited by 45 · see citing works

Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effectsPreprint

Petri, K., Kim, D. Y., Sasaki, K. E., Canver, M. C., Wang, X., Shah, H., Lee, H., Horng, J. E., Clement, K., Iyer, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.05.438458 · Cited by 42 · see citing works

PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization

Zafrir, B., Egbaria, A., Stein, N., Elis, A., & Saliba, W. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.11.004 · Cited by 40 · see citing works

Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins

Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.021 · Cited by 668 · see citing works

Past, present, and future of CRISPR genome editing technologies

Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609 · see citing works

Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges

Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259 · see citing works

Engineering a precise adenine base editor with minimal bystander editing

Chen, L., Zhang, S., Xue, N., Hong, M., Zhang, X., Zhang, D., Yang, J., Bai, S., Huang, Y., Meng, H., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01163-8 · Cited by 202 · see citing works

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside

Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187 · see citing works

The dawn of a new era of targeted lipid-lowering therapies

Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171 · see citing works

Non-liver mRNA Delivery

Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173 · see citing works

Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease

Palanki, R., Bose, S. K., Dave, A., White, B. M., Berkowitz, C., Luks, V., Yaqoob, F., Han, E., Swingle, K. L., Menon, P., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c02268 · Cited by 77 · see citing works

Expanding biology of PCSK9: roles in atherosclerosis and beyond

Seidah, N. G., & Garçon, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01057-z · Cited by 76 · see citing works

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology

Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67 · see citing works

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57 · see citing works

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study

Fang, S., Yarmolinsky, J., Gill, D., Bull, C. J., Perks, C. M., the PRACTICAL Consortium, Davey Smith, G., Gaunt, T. R., & Richardson, T. G. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1003988 · Cited by 55 · see citing works

PCSK9 in metabolism and diseases

Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49 · see citing works

Emerging applications of gene editing technologies for the development of climate-resilient crops

Chavhan, R. L., Jaybhaye, S. G., Hinge, V. R., Deshmukh, A. S., Shaikh, U. S., Jadhav, P. K., Kadam, U. S., & Hong, J. C. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1524767 · Cited by 43 · see citing works

New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing

Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31 · see citing works

PCSK9-directed therapies: an update

Katzmann, J. L., & Laufs, U. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000919 · Cited by 22 · see citing works

The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment

Testa, G., Giannelli, S., Staurenghi, E., Cecci, R., Floro, L., Gamba, P., Sottero, B., & Leonarduzzi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413637 · Cited by 14 · see citing works

PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications

Wang, J. D. J., Teo, A. Y. T., Xiao, B., Chao, Y., Zhou, Z. D., Tan, B. J.-W., Chan, L.-L., Rosalie, E., & Tan, E.-K. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00568-y

Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells

Hunt, J., Samson, C., du Rand, A., & Sheppard, H. M. (2023) · Human Genetics · doi:10.1007/s00439-023-02561-1 · Cited by 125 · see citing works

Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review

Ebrahimi, V., & Hashemi, A. (2020) · Gene · doi:10.1016/j.gene.2020.144813 · Cited by 32 · see citing works

Strategies for Optimization of the Clustered Regularly Interspaced Short Palindromic Repeat-Based Genome Editing System for Enhanced Editing Specificity

Wang, Y., Wang, H., Jian, Y.-Z., Luo, Z., Shao, H., & Zhang, W. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.283 · Cited by 3 · see citing works

CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases

Antony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 18 · see citing works

CRISPR–Cas9 gene editing induced complex on-target outcomes in human cells

Wen, W., & Zhang, X. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.002 · Cited by 38 · see citing works